{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T21:31:19Z","timestamp":1772227879852,"version":"3.50.1"},"reference-count":14,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clbc.2014.04.007","type":"journal-article","created":{"date-parts":[[2014,6,2]],"date-time":"2014-06-02T09:04:41Z","timestamp":1401699881000},"page":"413-416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen"],"prefix":"10.1016","volume":"14","author":[{"given":"Kathryn J.","family":"Ruddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"DeSantis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Barry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline C.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Borges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann H.","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2014.04.007_bib1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jamcollsurg.2008.12.001","article-title":"Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease","volume":"208","author":"Gnerlich","year":"2009","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.clbc.2014.04.007_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s10549-007-9510-2","article-title":"Study of time-course changes in annual recurrence rates for breast cancer: data analysis of 2,209 patients for 10 years post-surgery","volume":"106","author":"Kimura","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2014.04.007_bib3","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/annonc\/mdg452","article-title":"Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients","volume":"14","author":"Arriagada","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2014.04.007_bib4","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","article-title":"Annual hazard rates of recurrence for breast cancer after primary therapy","volume":"14","author":"Saphner","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.04.007_bib5","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2014.04.007_bib6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(05)67059-6","article-title":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial","volume":"366","author":"Jakesz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2014.04.007_bib7","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2005.04.120","article-title":"Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial","volume":"23","author":"Boccardo","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.04.007_bib8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A\u00a0randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clbc.2014.04.007_bib9","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1200\/JCO.2010.34.4010","article-title":"Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover","volume":"30","author":"Jin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2014.04.007_bib10","unstructured":"International Breast Cancer Study Group (IBCSG). Available at: www.ibcsg.org."},{"key":"10.1016\/j.clbc.2014.04.007_bib11","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"10.1016\/j.clbc.2014.04.007_bib12","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2014.04.007_bib13","doi-asserted-by":"crossref","unstructured":"Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. American Society of Clinical Oncology. Chicago, IL, 2013.","DOI":"10.1200\/jco.2013.31.18_suppl.5"},{"key":"10.1016\/j.clbc.2014.04.007_bib14","unstructured":"Partridge AH. Reducing late recurrence of hormone receptore\u2013positive breast cancer: patience is a virtue. American Society of Clinical Oncology. Plenary Discussion. Chicago, IL, 2013."}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914000913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820914000913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:13:07Z","timestamp":1761513187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820914000913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S1526820914000913"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2014.04.007","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2014.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}